INFANRIX hexa is a vaccine used in children for protection against diphtheria (respiratory and skin disease), tetanus (lockjaw), pertussis (whooping cough), hepatitis B, poliomyelitis (Polio) and Haemophilus influenzae type b diseases. Vaccination is …
Infanrix Hexa - European Medicines Agency (EMA)
Aug 11, 2014 · Infanrix hexa is a vaccine used to protect infants from six weeks of age and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by …
INFANRIX-Hexa | GSK Canada
Patient information: November 2, 2012 - Important information (PDF - 119 KB) for patients regarding the use of INFANRIX-Hexa. Vaccines - INFANRIX-Hexa.
INFANRIX | FDA - U.S. Food and Drug Administration
Oct 27, 2023 · INFANRIX is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years (prior to the seventh...
- [PDF]
INFANRIX HEXA - GSK
INFANRIX HEXA is a vaccine used to prevent six diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and Haemophilus influenzae type b (Hib). The vaccine works by causing the body to produce its own …
Infanrix hexa is indicated for primary and booster vaccination of infants from the age of 6 weeks and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by
Hexavalent vaccines in infants: a systematic literature review and …
Abstract. Introduction: The hexavalent vaccine DT3aP-HBV-IPV-Hib (Infanrix hexa, GSK) was first licensed in Europe in 2000. DT2aP-HBV-IPV-Hib (Hexyon/Hexacima/Hexaxim, Sanofi Pasteur), and DT5aP-HBV-IPV-Hib (Vaxelis, MCM Vaccine Company) were licensed in the EU in 2013 and 2016, respectively, based largely on studies demonstrating non ...
Safety profile of Infanrix hexa - 17 years of GSK's passive post ...
Introduction: This paper reports 17 years of passive safety surveillance of routine use of the pediatric hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus- Haemophilus influenzae type b-conjugate vaccine (DTPa-HBV-IPV/Hib, Infanrix hexa, GSK). Methods: Global post-licensure passive surveillance data collected ...
Infanrix Hexa | GSK AU
Infanrix Hexa Product: combined Diphtheria-Tetanus-acellular Pertussis (DTPa), hepatitis B, poliovirus and haemophilus influenzae type B vaccine Consumer Medicine Information
Full article: Safety profile of Infanrix hexa – 17 years of GSK’s ...
Aug 10, 2020 · The combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine (DTPa-HBV-IPV/Hib; Infanrix hexa, GSK), indicated for primary and booster vaccination of infants and toddlers, is the pediatric hexavalent vaccine that has been the longest on the market [Citation 1 ...